Bioline RX Ltd Sponsored ADR Aktie News

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.

Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers) Patent further broadens and strengthens GLIX1 patent protection until 2040, with a possible patent-term extension of up to five years TEL AVIV, Israel , Nov. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stag...

BioLineRx Ltd. - Special Call Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.

- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - - BioLineRx affirms its cash runway into the first half of 2027 - - Management to host con...

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Irina Koffler - Corporate Participant Mali Zeevi - Chief Financial Officer Philip A.

- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash runway guidance into H1 2027 -- Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel , Aug. 14, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX),...

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.

Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts' expectations.